Imperva Inc (IMPV) Stock Rating Reaffirmed by Stephens
Imperva Inc (NYSE:IMPV)‘s stock had its “overweight” rating restated by Stephens in a research note issued on Thursday. They presently have a $61.00 price objective on the software maker’s stock, up from their prior price objective of $53.00. Stephens’ target price suggests a potential upside of 19.96% from the stock’s current price.
Several other research analysts also recently issued reports on the company. ValuEngine downgraded Imperva from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BidaskClub downgraded Imperva from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 5th. Susquehanna Bancshares Inc began coverage on Imperva in a research note on Wednesday, June 7th. They issued a “positive” rating and a $60.00 price objective for the company. UBS AG began coverage on Imperva in a research note on Tuesday, June 6th. They issued a “positive” rating and a $60.00 price objective for the company. Finally, Evercore ISI reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Imperva in a research note on Monday, May 15th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company. Imperva presently has a consensus rating of “Hold” and a consensus target price of $50.29.
Shares of Imperva (NYSE IMPV) opened at 50.85 on Thursday. The stock’s 50 day moving average is $49.16 and its 200 day moving average is $43.54. The firm’s market cap is $1.70 billion. Imperva has a 12 month low of $34.40 and a 12 month high of $57.24.
Imperva (NYSE:IMPV) last released its quarterly earnings data on Thursday, May 4th. The software maker reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.33. Imperva had a return on equity of 36.67% and a net margin of 31.92%. The company had revenue of $72.31 million during the quarter, compared to the consensus estimate of $68.16 million. During the same quarter in the prior year, the firm posted ($0.25) earnings per share. The firm’s revenue was up 21.0% compared to the same quarter last year. Analysts forecast that Imperva will post $0.45 EPS for the current fiscal year.
In other news, insider Amichai Shulman sold 3,089 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $48.70, for a total transaction of $150,434.30. Following the completion of the sale, the insider now owns 100,151 shares of the company’s stock, valued at approximately $4,877,353.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CRO Michael D. Mooney sold 52,356 shares of the firm’s stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $47.51, for a total transaction of $2,487,433.56. Following the sale, the executive now directly owns 52,356 shares of the company’s stock, valued at approximately $2,487,433.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 60,302 shares of company stock valued at $2,875,861. Insiders own 2.20% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Imperva by 4.6% in the first quarter. Vanguard Group Inc. now owns 2,339,441 shares of the software maker’s stock valued at $96,033,000 after buying an additional 102,779 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Imperva by 2.2% in the first quarter. JPMorgan Chase & Co. now owns 1,627,998 shares of the software maker’s stock valued at $66,828,000 after buying an additional 34,653 shares during the period. Clearbridge Investments LLC increased its stake in shares of Imperva by 47.0% in the first quarter. Clearbridge Investments LLC now owns 1,262,507 shares of the software maker’s stock valued at $51,826,000 after buying an additional 403,809 shares during the period. Eagle Asset Management Inc. increased its stake in shares of Imperva by 4.1% in the first quarter. Eagle Asset Management Inc. now owns 1,087,223 shares of the software maker’s stock valued at $44,630,000 after buying an additional 43,278 shares during the period. Finally, North Run Capital LP increased its stake in shares of Imperva by 999.3% in the first quarter. North Run Capital LP now owns 750,000 shares of the software maker’s stock valued at $30,788,000 after buying an additional 681,772 shares during the period. 92.72% of the stock is owned by institutional investors.
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.